Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

The Effect of a Single Intravenous Injection of Esketamine During Cesarean Section on Postoperative Pruritus in Patients With Intrahepatic Cholestasis of Pregnancy

NCT07560722 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-05-05
Last updated
2026-05-01

Condition(s) studied

Intrahepatic Cholestasis of Pregnancy

Investigational drug(s) / intervention(s)

Normal Saline (0.9% NaCl)Esketamine 0.3mg/kg →

Normal Saline (0.9% NaCl): The same volume of normal saline was injected after fetal delivery during the operation

Esketamine 0.3mg/kg: Esketamine 0.3mg/kg was given intravenously after fetal delivery during the operation

Study summary

To explore the effect of a single intravenous injection of esketamine during cesarean section on postoperative pruritus in patients with intrahepatic cholestasis of pregnancy.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age: 18 - 40 years old; Gestational age: ≥ 35 weeks; Singleton pregnancy. 2. Clear consciousness, able to cooperate with NRS scoring, laboratory tests and follow-up. 3. Meet the diagnostic criteria of the "Clinical Diagnosis, Treatment and Management Guidelines for Intrahepatic Cholestasis of Pregnancy (2024 Edition)" : fasting serum TBA≥10 μmol/L or postprandial serum TBA≥19 μmol/L. 4. Reporting pruritus NRS ≥ 4 points twice within one week. 5. Planned to undergo cesarean section under intraspinal anesthesia. 6. ASA classification: I - III grade. Exclusion Criteria: 1. Those who are known to be allergic to the drug components or have an allergic constitution. 2. Related to the safe use of esketamine: history of mental illness; uncontrolled hypertension; uncontrolled hyperthyroidism; increased intracranial pressure, increased intraocular pressure; long-term alcohol consumption or drug abuse history. 3. Those with severe organic diseases and liver diseases. 4. Those with malignant tumors. 5. Other pruritic diseases: uremic pruritus, true erythrocytosis, cutaneous T-cell lymphoma, eosinophilia, drug rash and drug-induced pruritus, and other pruritic diseases that are easily confused, such as atopic dermatitis, pemphigus, scabies, parasitic delusionism, artificial dermatitis, etc. 6. Eclampsia and pre-eclampsia, HELLP syndrome; fetal developmental abnormalities, multiple pregnancies. 7. ASA classification as grade IV. 8. Those with poor compliance and unable to complete the trial according to the research protocol. 9. Those who have participated in other drug clinical trials within the past 4 weeks. 10. Due to any reason, the researchers consider that there is any situation that is not suitable for inclusion. \-

Primary outcome measure(s)

  • NRS pruritus score at 24 hours after surgery — 24 hours after the surgery
    The patient evaluated the intensity of pruritus with 11 numbers ranging from 0 to 10, and the higher the number, the more severe the condition. The higher the number, the more severe the itching. 0: No sensation. 1-3: Mild itching. 4-6: Moderate itching. 7-9: Severe itching. 10: Extremely severe itching.

Trial sites (1)

FacilityCityRegionStatus
Tianjin Medical University General Hospital Tianjin China
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07560722 on ClinicalTrials.gov ↗ ← All trials in China